Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03320330 · ClinicalTrials.gov registry record · Phase 1
Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors
A Phase 1 study of Refractory Malignant Solid Neoplasm and Recurrent Malignant Solid Neoplasm, sponsored by Children's Oncology Group.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
- 20
- Study locations
NCT03320330: Completed Phase 1 study of Refractory Malignant Solid Neoplasm and Recurrent Malignant Solid Neoplasm, sponsored by Children's Oncology Group.
NCT03320330 is a Phase 1 study of Refractory Malignant Solid Neoplasm and Recurrent Malignant Solid Neoplasm that has completed, run by Children's Oncology Group. The registered enrollment target is 26 participants, below the 64-participant average among 59 other Refractory Malignant Solid Neoplasm trials with a reported enrollment target (59% lower). The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03320330, a Phase 1 study of Refractory Malignant Solid Neoplasm and Recurrent Malignant Solid Neoplasm, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase I/II trial studies the side effects and best dose of pepinemab and to see how well it works in treating younger patients with solid tumors that have come back after treatment, or do not respond to treatment. Immunotherapy with monoclonal antibodies, such as pepinemab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Primary Outcome
Frequency (%) of patients with dose limiting toxicities by dose level and study part.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- OTHER Pharmacological Study
- BIOLOGICAL Pepinemab
Study Locations (20)
California
- Children's Hospital Los Angeles - Los Angeles
- Children's Hospital of Orange County - Orange
- UCSF Medical Center-Mission Bay - San Francisco
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
- Children's Hospital of Pittsburgh of UPMC - Pittsburgh
Alabama
- Children's Hospital of Alabama - Birmingham
Colorado
- Children's Hospital Colorado - Aurora
Connecticut
- Yale University - New Haven
District of Columbia
- Children's National Medical Center - Washington D.C.
Georgia
- Children's Healthcare of Atlanta - Egleston - Atlanta
Illinois
- Lurie Children's Hospital-Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2018-01-31 |
| Est. Completion | 2024-06-30 |
| Phase | Phase 1 |
What the finished NCT03320330 record still lists
NCT03320330 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 64-participant average among 59 other Refractory Malignant Solid Neoplasm trials with a reported enrollment target (59% lower).
The record links to 4 conditions, with Refractory Malignant Solid Neoplasm appearing as the primary indexed condition, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT03320330 names 20 study sites across 17 states, led by California, Pennsylvania, Alabama.
Frequently Asked Questions
What is clinical trial NCT03320330 about?
NCT03320330 is a clinical study titled "Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors". This phase I/II trial studies the side effects and best dose of pepinemab and to see how well it works in treating younger patients with solid tumors that have come back after treatment, or do not respond to treatment. Immunotherapy with monoclonal antibodies, such as pepinemab, may help the body's ...
What is the current status of trial NCT03320330?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2018-01-31. Estimated completion is 2024-06-30.
What conditions does trial NCT03320330 study?
This clinical trial studies the following conditions: Refractory Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Osteosarcoma, Refractory Osteosarcoma.
What interventions are being tested in trial NCT03320330?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Pharmacological Study (OTHER), Pepinemab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03320330?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03320330 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Refractory Malignant Solid Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03320330's enrollment target sits among peer trials
26 46th of 59 higher than 14 of 59 other Refractory Malignant Solid Neoplasm trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Refractory Malignant Solid Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors
RECRUITING · Phase 1
-
Studying TAK-243 in Patients With Advanced Cancer
RECRUITING · Phase 1
-
Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease
RECRUITING · Phase 1
-
Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma
RECRUITING · Phase 1
-
AOH1996 for the Treatment of Refractory Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI